drugset / Trial / NCT02195323

Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)

NCT02195323

Phase 1 Completed 7 enrolled Royan Institute
NaSingle-groupOpen-labelTreatment

Summary

This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD).

Timeline

Start
2014-04
Primary completion
2015-12
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous